Description of the medicine: Latanoprost (Latanoprost)
[3,5-Dioxo-2 (3-hydroxy-5-phenyl-pentyl) cyclopentyl] -1-pentyl ester of heptanoic acid.
Synthetic eicosanoid of the prostaglandin group F 2α .
Of the pharmacological properties of latanoprost, special attention was paid to its ability to cause a decrease in intraocular pressure (IOP) in patients with open-angle glaucoma in small concentrations and it began to be produced abroad in the form of eye drops for ophthalmic practice under the name “Xalatan”. Under the same name, it is registered and used in the Russian Federation.
Xalatan (Xalatan) - 0.005% aqueous solution of latanoprost with the addition of a stabilizer - sodium dihydrogen phosphate, an antiseptic - benzalkonium chloride, sodium chloride. Colorless transparent liquid.
The drug reduces IOP by stimulating the outflow of intraocular moisture through the muscle fibers of the ciliary body into the suprachoroid space and then out through the sclera. The systemic arterial pressure and respiration have no significant effect.
They are mainly used for open-angle glaucoma, as well as for the ineffectiveness of other drugs used to reduce intraocular pressure.
The drug penetrates well through the cornea. When instilled, a decrease in IOP is observed after 3-4 hours, reaches a maximum after 8-12 hours and lasts up to 24 or more hours.
Xalatan is instilled 1 drop in a sick eye 1 time per day (in the evening). It is noted that an increase in the number of drops does not increase, but reduces the effectiveness of the drug.
By the strength of the hypotensive effect against IOP, xalatan practically corresponds to the action of a 0.5% solution (eye drops) of timolol and its analogues.
Usually the drug is well tolerated (miosis is not observed).
Possible side effects: sensation of mild pain in the eye, conjunctival hyperemia, allergic reactions. A characteristic side effect is an increase (after a relatively long application of 3-4 months or more) of pigmentation of the iris (in which it was instilled) from blue to brown, sometimes leading to heterochromia of the eye. Dark color can acquire eyelashes and skin around the eyes.
The drug is contraindicated in pregnancy and lactation.
Xalatan can be used in combination with other anti-glaucomatous drugs.
Release form: 0.005% solution in 2.5 ml bottles (a smaller amount of the drug in one package compared to other antihypertensive eye drops is explained by its relatively low stability). Apply xalatan after opening the bottle should be no more than 4 weeks.